Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAR T induced resistance in ALL

Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

Key clinical point: Unintentional transduction of a single leukemic B cell induced resistance to CTL019 (tisagenlecleucel) therapy.

Major finding: A patient with B-cell acute lymphoblastic leukemia (B-ALL) had frank relapse 9 months after a CTL019 infusion, with more than 90% bone marrow infiltration of chimeric antigen receptor–transduced B-cell leukemia cells.

Study details: A case study of a 20-year-old male with B-ALL undergoing CTL019 therapy.

Disclosures: Study funding was provided by Bristol-Myers Squibb, Novartis, the National Institutes of Health, and others. Dr. Ruella and several of his colleagues work under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research and are inventors of intellectual property licensed by the University of Pennsylvania to Novartis.

Read the article here.

Citation:

Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9.

This Week's Must Reads

Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31

Bortezomib looks promising in WM mutations, Sklavenitis-Pistofidis R et al. Blood. 2018 Oct 26. doi: 10.1182/blood-2018-07-863241

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

Positive results for rituximab biosimilar in comparative trial, Ogura M et al. Lancet Haematol. 2018 Nov;5(11):e543-53

Patient blood management in stem cell transplant, Jambhekar N et al. AABB 2018, Abstract PBM3-ST4-22

Must Reads in Leukemia, Myelodysplasia, Transplantation

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

New Choosing Wisely Guidance on BMT Released , Biol Blood Marrow Transplant; ePub 2018 Jan 19; Bhella, et al

Second Primary Malignancies in Patients with MM, Biol Blood Marrow Transplant; ePub 2018 Jan 12; Sahebi, et al

Progression to MM in Patients with MGUS Assessed, N Engl J Med; 2018 Jan 18; Kyle, Larson, et al

These 2 Markers May Impact MGUS Progression to MM , Leuk Lymphoma; ePub 2018 Jan 18; Vallet, et al